Quizartinib High Dose + Quizartinib Low Dose
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, Leukemia
Trial Timeline
Jul 18, 2025 → Jul 14, 2032
NCT ID
NCT06824168About Quizartinib High Dose + Quizartinib Low Dose
Quizartinib High Dose + Quizartinib Low Dose is a phase 2 stage product being developed by Daiichi Sankyo for Acute Myeloid Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06824168. Target conditions include Acute Myeloid Leukemia, Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06824168 | Phase 2 | Recruiting |
Competing Products
20 competing products in Acute Myeloid Leukemia